Douglas Scott Johnson
12Patents
4h-index
39Co-inventors
56Inventor score
Filing activity: Apr 16, 2001 → Aug 21, 2019
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7160888B2 | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia | Human Necessities | 42 | Expired |
| US8916564B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | Human Necessities | 5 | Active |
| US9845301B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | Chemistry; Metallurgy | 5 | Active |
| US8697673B2 | Bicyclic pyridinones | Chemistry; Metallurgy | 4 | Active |
| US8044052B2 | Biaryl ether urea compounds | Chemistry; Metallurgy | 3 | Active |
| US10428034B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | Chemistry; Metallurgy | 1 | Active |
| US9765073B2 | Cyclopropabenzofuranyl pyridopyrazinediones | Human Necessities | 0 | Active |
| US10723711B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | Chemistry; Metallurgy | 0 | Active |
| US9751877B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | Human Necessities | 0 | Active |
| US9193726B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | Human Necessities | 0 | Active |
| US9067934B2 | Bicyclic pyridinones | Chemistry; Metallurgy | 0 | Active |
| US6943183B2 | 5-substituted tetralones as inhibitors of ras farnesyl transferase | Chemistry; Metallurgy | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.